keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal Serogroup B Vaccine

keyword
https://www.readbyqxmd.com/read/28520709/updated-recommendations-for-use-of-menb-fhbp-serogroup-b-meningococcal-vaccine-advisory-committee-on-immunization-practices-2016
#1
Monica E Patton, David Stephens, Kelly Moore, Jessica R MacNeil
Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B(†)) (4)...
May 19, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28505234/increased-risk-for-meningococcal-disease-among-men-who-have-sex-with-men-in-the-united-states-2012-2015
#2
Temitope A Folaranmi, Cecilia B Kretz, Hajime Kamiya, Jessica R MacNeil, Melissa J Whaley, Amy Blain, Mike Antwi, Marie Dorsinville, Massimo Pacilli, Shamika Smith, Rachel Civen, Van Ngo, Kathleen Winter, Kathleen Harriman, Xin Wang, Virginia B Bowen, Manisha Patel, Stacey Martin, Lara Misegades, Sarah A Meyer
Background: Several clusters of serogroup C meningococcal disease among men who have sex with men (MSM) have been reported in the United States in recent years. The epidemiology and risk of meningococcal disease among MSM is not well-described. Methods: All meningococcal disease cases among men aged 18-64 years reported to the National Notifiable Disease Surveillance System between January 2012 and June 2015 were reviewed. Characteristics of meningococcal disease cases among MSM and men not known to be MSM (non-MSM) were described...
May 13, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28498097/the-asplenic-patient-post-insult-immunocompetence-infection-and-vaccination
#3
Brandon Dionne, Walter Dehority, Meghan Brett, Thomas R Howdieshell
BACKGROUND: Splenic injury can occur through multiple mechanisms and may result in various degrees of residual immunocompetence. Functionally or anatomically asplenic patients are at higher risk for infection, particularly with encapsulated bacteria. Vaccination is recommended to prevent infection with these organisms; however, the recommendations are routinely updated, and vaccine selection and timing are complex. METHODS: Review of the pertinent English-language literature, including the recommendations of the U...
May 12, 2017: Surgical Infections
https://www.readbyqxmd.com/read/28495657/outer-membrane-vesicles-extracted-from-neisseria-meningitidis-serogroup-x-for-prevention-of-meningococcal-disease-in-africa
#4
Reinaldo Acevedo, Caridad Zayas, Gunnstein Norheim, Sonsire Fernández, Barbara Cedré, Yisabel Aranguren, Maribel Cuello, Yaimara Rodriguez, Humberto González, Aleida Mandiarote, Marylin Pérez, Maritza Hernández, Mabel Hernández-Cedeño, Domingo González, Sverre-Henning Brorson, Einar Rosenqvist, Lisbeth Naess, Gro Tunheim, Daniel Cardoso, Luis García
Meningococcal disease is caused mainly by serogroups A, B, C, Y, W of N. meningitidis. However, numerous cases of meningitis caused by serogroup X N. meningitidis (MenX) have recently been reported in several African countries. Currently, there are no licensed vaccines against this pathogen and most of the MenX cases have been caused by meningococci from clonal complex (c.c) 181. Detergent extracted meningococcal outer membrane vesicle (dOMV) vaccines have previously shown to be safe and effective against epidemics of serogroup B meningococcal disease in all age groups...
May 8, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28487177/predicted-vs-observed-effectiveness-of-outer-membrane-vesicle-omv-vaccines-against-meningococcal-serogroup-b-disease-systematic-review
#5
Thomas Harder, Judith Koch, Ole Wichmann, Wiebke Hellenbrand
IMPORTANCE: Human serum bactericidal antibody levels (hSBA) are commonly used as an immune correlate of protection after vaccination against meningococcal disease. We performed a systematic review of how well this marker correlates with protection induced by outer membrane vesicle (OMV) vaccines against meningococcal B (MenB) disease. OBJECTIVE: To compare vaccine effectiveness (VE) of OMV vaccines against MenB predicted by hSBA (predicted protection) to VE from clinical studies (observed protection)...
May 6, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28473508/uk-parents-attitudes-towards-meningococcal-group-b-menb-vaccination-a-qualitative-analysis
#6
Cath Jackson, Joanne Yarwood, Vanessa Saliba, Helen Bedford
OBJECTIVES: (1) To explore existing knowledge of, and attitudes, to group B meningococcal disease and serogroup B meningococcal (MenB) vaccine among parents of young children. (2) To seek views on their information needs. DESIGN: Cross-sectional qualitative study using individual and group interviews conducted in February and March 2015, prior to the introduction of MenB vaccine (Bexsero) into the UK childhood immunisation schedule. SETTING: Community centres, mother and toddler groups, parents' homes and workplaces in London and Yorkshire...
May 4, 2017: BMJ Open
https://www.readbyqxmd.com/read/28465304/invasive-meningococcal-disease-in-the-veneto-region-of-italy-a-capture-recapture-analysis-for-assessing-the-effectiveness-of-an-integrated-surveillance-system
#7
Tatjana Baldovin, Roberta Lazzari, Silvia Cocchio, Patrizia Furlan, Chiara Bertoncello, Mario Saia, Francesca Russo, Vincenzo Baldo
BACKGROUND: Epidemiology of Neisseria meningitidis has been changing since the introduction of universal vaccination programmes against meningococcal serogroup C (MenC) and meningococcal serogroup B (MenB) has now become dominant. This study aimed to analyse the cases reported in institutional data recording systems to estimate the burden of invasive meningococcal diseases (IMDs) and assess the effectiveness of surveillance in Veneto region (Italy). METHODS: Analysis was performed from 2007 to 2014 on data recorded in different systems: Mandatory Notification System, National Surveillance of Invasive Bacterial Diseases System and Laboratories Surveillance System (LSS), which were pooled into a combined surveillance system (CSS) and hospital discharge records (HDRs)...
May 2, 2017: BMJ Open
https://www.readbyqxmd.com/read/28455205/meningococcal-disease-in-the-middle-east-and-africa-findings-and-updates-from-the-global-meningococcal-initiative
#8
REVIEW
Ray Borrow, Dominique A Caugant, Mehmet Ceyhan, Hannah Christensen, Ener Cagri Dinleyici, Jamie Findlow, Linda Glennie, Anne Von Gottberg, Amel Kechrid, Julio Vázquez Moreno, Aziza Razki, Vincent Smith, Muhamed-Kheir Taha, Hassiba Tali-Maamar, Khalid Zerouali
The Global Meningococcal Initiative (GMI) has recently considered current issues in Middle Eastern and African countries, and produced two recommendations: (i) that vaccination of attendees should be considered for some types of mass-gathering events, as some countries mandate for the Hajj, and (ii) vaccination of people with human immunodeficiency virus should be used routinely, because of increased meningococcal disease (MD) risk. Differences exist between Middle Eastern and African countries regarding case and syndrome definitions, surveillance, and epidemiologic data gaps...
April 25, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28441109/meningococcal-serogroup-b-vaccine-knowledge-and-acceptability-among-parents-in-italy
#9
Teresa Morrone, Francesco Napolitano, Luciana Albano, Gabriella Di Giuseppe
This study aimed to evaluate the knowledge and attitudes about Meningococcal meningitis B and the relative vaccine for children among a sample of parents in Italy. A cross-sectional investigation was conducted from October to December 2015 among a sample of 910 parents in the geographic area of Naples and Salerno (Italy). In total, 543 of 910 parents returned a completed questionnaire for a response rate of 59.7%. Almost all parents had heard about meningitis (95.8%), 79.8% of these knew the mode of transmission (through respiratory droplets) and 62...
April 25, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28433330/bivalent-rlp2086-trumenba%C3%A2-development-of-a-well-characterized-vaccine-through-commercialization
#10
Khurram Sunasara, John Cundy, Sriram Srinivasan, Brad Evans, Weiqiang Sun, Scott Cook, Eric Bortell, John Farley, Daniel Griffin, Michele Bailey Piatchek, Katherine Arch-Douglas
The phrase "Process is the Product" is often applied to biologics, including multicomponent vaccines composed of complex components that evade complete characterization. Vaccine production processes must be defined and locked early in the development cycle to ensure consistent quality of the vaccine throughout scale-up, clinical studies, and commercialization. This approach of front-loading the development work helped facilitate the accelerated approval of the Biologic License Application for the well-characterized vaccine bivalent rLP2086 (Trumenba®, Pfizer Inc) in 2014 under Breakthrough Therapy Designation...
April 19, 2017: Vaccine
https://www.readbyqxmd.com/read/28418307/serogroup-b-meningococcal-disease-vaccine-recommendations-at-a-university-new-jersey-usa-2016
#11
Heidi M Soeters, Jill Dinitz-Sklar, Prathit A Kulkarni, Jessica R MacNeil, Lucy A McNamara, Elizabeth Zaremski, How-Yi Chang, Eduardo Lujan, Dan Granoff, Melodee Lasky, Barbara Montana
In response to a university-based serogroup B meningococcal disease outbreak, the serogroup B meningococcal vaccine Trumenba was recommended for students, a rare instance in which a specific vaccine brand was recommended. This outbreak highlights the challenges of using molecular and immunologic data to inform real-time response.
May 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28375029/emerging-experience-with-meningococcal-serogroup-b-protein-vaccines
#12
REVIEW
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli
The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials...
May 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28368526/licensed-meningococcal-serogroup-b-vaccine-induced-immunity-against-invasive-disease-does-not-reflect-protection-against-nasal-colonization-in-a-humanized-mouse-model
#13
Carolyn M Buckwalter, Elissa G Currie, Raymond S W Tsang, Scott D Gray-Owen
Background: The 4CMenB vaccine is an outer membrane vesicle and recombinant protein-based vaccine recently licensed to protect against serogroup B meningococcal disease. It remains unknown whether this vaccine will prevent carriage or transmission, key aspects in long-term vaccine success and disease eradication. Methods: Employing a 'humanized' transgenic mouse model of nasal colonization, a systematic approach was taken to estimate the potential for carriage prevention against antigenically-diverse Neisseria meningitidis strains, and to compare this protection to an invasive meningococcal disease challenge model...
March 27, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28366725/meningococcal-serogroup-b-strain-coverage-of-the-multicomponent-4cmenb-vaccine-with-corresponding-regional-distribution-and-clinical-characteristics-in-england-wales-and-northern-ireland-2007-08-and-2014-15-a-qualitative-and-quantitative-assessment
#14
Sydel R Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray Borrow
BACKGROUND: The UK introduced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisation programme in September, 2015. The Meningococcal Antigen Typing System (MATS) was used to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 in England and Wales (MATS coverage). We aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15, before 4CMenB introduction; compare strain coverage between 2007-08 and 2014-15; and investigate associations between MATS coverage, age, region, and disease outcomes...
March 30, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28356256/recent-progress-in-the-prevention-of-serogroup-b-meningococcal-disease
#15
REVIEW
Ian M Feavers, Martin C J Maiden
The widespread use of meningococcal polysaccharide conjugate vaccines has highlighted the challenge of providing protection against serogroup B disease. Over a period of 4 decades, vaccine development has focused on subcapsular protein antigens, first with outer membrane vesicle (OMV) vaccines against epidemic outbreaks, and more recently on new multicomponent vaccines designed to offer better cross-protection against the antigenically diverse strains responsible for endemic disease. Because of the low incidence of meningococcal disease, the protective efficacy of these vaccines has not been determined in clinical studies, and their licensure has been based on serological data; however, the serological assays used to predict protective coverage have limitations...
May 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28351732/prevalence-of-factor-h-binding-protein-sub-variants-among-neisseria-meningitidis-in-china
#16
Fenglin Shi, Aiyu Zhang, Bingqing Zhu, Yuan Gao, Li Xu, Yixing Li, Zundong Yin, Junhong Li, Na Xie, Zhujun Shao
OBJECTIVE: To study the prevalence of the fHbp genes in Neisseria meningitidis (N. meningitidis) isolates for further evaluation and development of serogroup B meningococcal vaccines in China. METHODS: A panel of 1012 N. meningitidis strains was selected from the national culture collection from 1956 to 2016, according to the years of isolation, locations, and strain sources. These were tested by FHbp variant typing. Multi-locus sequence typing (MLST) was performed on 822 of these samples, including 242 strains from clinical strains and 580 carrier-derived strains...
March 25, 2017: Vaccine
https://www.readbyqxmd.com/read/28347501/knowledge-attitudes-beliefs-and-behaviors-of-university-students-faculty-and-staff-during-a-meningococcal-serogroup-b-outbreak-vaccination-program
#17
D M MacDougall, J M Langley, L Li, L Ye, D MacKinnon-Cameron, K A Top, S A McNeil, B A Halperin, A Swain, J A Bettinger, E Dubé, G De Serres, S A Halperin
OBJECTIVES: During an outbreak of invasive meningococcal B disease on a university campus, we explored the knowledge, attitudes, beliefs, and behaviors of members of the university community in relation to the disease, the vaccine, and the vaccination program. DESIGN: All students, faculty and staff were invited by email to participate in a 71-item online survey, which was administered after completion of the mass clinics for the first and second doses of a meningococcal B vaccination program...
March 24, 2017: Vaccine
https://www.readbyqxmd.com/read/28344804/multicomponent-meningococcal-b-vaccination-4cmenb-of-adolescents-and-college-students-in-the-united-states
#18
REVIEW
Angelika Banzhoff
Meningococcal disease is rare, easily misdiagnosed, and potentially deadly. Diagnosis in the early stages is difficult and the disease often progresses extremely rapidly. In North America, the incidence of invasive meningococcal disease (IMD) is highest in infants and young children, with a secondary peak in adolescents, a population predominantly responsible for the carriage of disease. Neisseria meningitidis serogroup B (MenB) accounts for a large proportion of meningococcal disease in North America, with documented outbreaks in three universities in the United States (US) during 2008-2013...
February 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28343777/neisseria-meningitidis-nasopharyngeal-carriage-during-the-hajj-a-cohort-study-evaluating-the-need-for-ciprofloxacin-prophylaxis
#19
Ziad A Memish, Jaffar A Al-Tawfiq, Malak Almasri, Esam I Azhar, Muhammad Yasir, Muneera S Al-Saeed, Huda Ben Helaby, Ray Borrow, Abdulhafeez Turkistani, Abdallah Assiri
BACKGROUND: The annual Muslim pilgrimage has the potential of increase risk for acquisition of Neisseria meningitidis. Here, we evaluate the Hajj impact on the prevalence of N. meningitidis carriage in a paired and non-paired cohort of pilgrims. Secondary objectives were to calculate the compliance with recommended vaccination. METHODS: This is a prospective paired (arriving and departing), non-paired arriving and non-paired departing cohort study with the collection of nasopharyngeal samples at the start and the end of the Hajj...
March 23, 2017: Vaccine
https://www.readbyqxmd.com/read/28334397/does-post-implementation-vaccine-effectiveness-data-support-pre-implementation-predictions-of-4cmenb-utility
#20
REVIEW
Jamie Findlow, Ray Borrow
Meningococcal serogroup B vaccines have been licensed on the basis of safety and immunogenicity data without efficacy studies. Establishing the breadth of coverage of these new vaccines has proved difficult and relied on correlates of protection such as serum bactericidal antibody and a novel assays such as the meningococcal antigen typing system. The demonstration of the effectiveness of 4CMenB in a reduced infant dose schedule together with detailed phenotypic and genotypic information gained from isolates and sera from cases of invasive MenB disease in vaccine eligible infants will enable a re-evaluation of our knowledge of correlates of protection...
March 1, 2017: Pathogens and Disease
keyword
keyword
49014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"